As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

The Asia–Pacific region has a high global burden of cardiovascular disease.1 The region, home to more than 60% of the world's population, spans the vast and diverse geographies from Oceania through ...

Governor Mike Braun announced the sale of the former GM Stamping Plant property in Indianapolis to Elanco Animal Health for $27 million on Monday.

Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced ...

The 18-acre estate features a 14,200-square-foot residence with five bedrooms and eight bathrooms, as well as a guest house.

Dining under palm trees on a patio at Mar-a-Lago in December, President-elect Donald Trump reassured chief executives at ...

Shares of Immuneering rose after the company entered into a clinical supply agreement for Eli Lilly's olomorasib drug to support testing of Immuneering's proposed lung-cancer treatment. The stock was ...

The state reportedly sold the site on the southwest side for $27 million, as part of Elanco's plans for a new headquarters.

Eli Lilly and Company is making headlines with a staggering 170% price increase for its weight-loss drug, Mounjaro, in the UK ...

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...

Eli Lilly and Company (NYSE: LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...